Inmed Pharmaceuticals Inc (INM)

May 19, 2026, 6:26 PM EDT - 1 hour ago

SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of InMed Pharmaceuticals, Inc. (Nasdaq – INM)

May 19, 2026, 8:30 AM EDT - 11 hours ago

InMed Pharmaceuticals Press release: M&A announcement

2026-05-19T12:15:35.000Z - 11 hours ago

InMed Pharmaceuticals and Mentari announce merger for migraine prevention

May 19, 2026, 8:00 AM EDT - 12 hours ago

InMed Pharmaceuticals & Mentari Therapeutics Announce Merger to Advance Migraine Prevention Therapies

2026-05-19T10:45:34.000Z - 13 hours ago

InMed Pharmaceuticals amends preferred investment options

May 19, 2026, 6:00 AM EDT - 14 hours ago

InMed Pharmaceuticals Amends Preferred Investment Options

May 6, 2026, 6:00 PM EDT - 13 days ago

InMed Reports Third Quarter Fiscal 2026 Financial Results and Provides Business Update

May 6, 2026, 7:00 AM EDT - 13 days ago

InMed Pharmaceuticals Quarterly report: Q3 2026

May 6, 2026, 7:00 AM EDT - 13 days ago

InMed Pharmaceuticals Earnings release: Q3 2026

Apr 27, 2026, 5:30 PM EDT - 22 days ago

InMed Pharmaceuticals Amends Preferred Investment Options

2026-03-30T15:22:11.000Z - 7 weeks ago

InMed receives Nasdaq notification regarding minimum bid price compliance

Mar 27, 2026, 5:04 PM EDT - 7 weeks ago

InMed Pharmaceuticals Receives Nasdaq Notification Regarding Minimum Bid Price Compliance

2026-03-23T11:50:08.000Z - 2 months ago

InMed Pharmaceuticals announces preclinical data on effects of INM-901

Mar 23, 2026, 7:30 AM EDT - 2 months ago

InMed Pharmaceuticals Announces Positive Data from Human Brain Organoid Neuroinflammation Models Supporting the INM-901 Alzheimer's Disease Program

2026-03-20T21:05:52.000Z - 2 months ago

InMed Pharmaceuticals files $50M mixed securities shelf

Mar 20, 2026, 8:00 AM EDT - 2 months ago

InMed Pharmaceuticals Registration statement: Registration filing

Mar 18, 2026, 1:45 PM EDT - 2 months ago

InMed Pharmaceuticals Transcript: Sidoti March Small-Cap Virtual Conference

2026-03-09T12:01:31.000Z - 2 months ago

InMed Pharmaceuticals provides development outlook for 2026

Mar 9, 2026, 7:30 AM EDT - 2 months ago

InMed Provides Update on Pharmaceutical Development Programs - Advancing Lead Drug Candidates Towards IND and Clinical Trial

Mar 6, 2026, 5:04 PM EST - 2 months ago

InMed Provides Update on BayMedica Operations and Strengthens Focus on Pharmaceutical Development Pipeline

Feb 11, 2026, 5:23 PM EST - 3 months ago

InMed Reports Second Quarter Fiscal 2026 Financial Results and Provides Business Update

Feb 11, 2026, 7:00 AM EST - 3 months ago

InMed Pharmaceuticals Earnings release: Q2 2026

Feb 11, 2026, 7:00 AM EST - 3 months ago

InMed Pharmaceuticals Quarterly report: Q2 2026

Dec 17, 2025, 8:00 PM EST - 5 months ago

InMed Announces Results of 2025 Annual General and Special Meeting

Dec 12, 2025, 5:31 PM EST - 5 months ago

InMed Provides Update on BayMedica Commercial Business

Dec 11, 2025, 2:00 PM EST - 5 months ago

InMed Pharmaceuticals Transcript: Life Sciences Virtual Investor Forum 2025

2025-11-18T14:47:56.000Z - 6 months ago

InMed announces completion of pharmacokinetic studies for Alzheimer’s candidate

Nov 18, 2025, 7:30 AM EST - 6 months ago

InMed Announces Successful Completion of Pharmacokinetic Studies in Large Animal Model for Its Alzheimer's Disease Candidate INM-901

Nov 6, 2025, 4:51 PM EST - 6 months ago

InMed Reports First Quarter Fiscal 2026 Financial Results and Provides Business Update

Nov 6, 2025, 4:00 PM EST - 6 months ago

InMed Pharmaceuticals Earnings release: Q1 2026

Nov 6, 2025, 4:00 PM EST - 6 months ago

InMed Pharmaceuticals Quarterly report: Q1 2026

Nov 3, 2025, 7:00 AM EST - 7 months ago

InMed Pharmaceuticals Proxy statement: Proxy Filing

Nov 3, 2025, 7:00 AM EST - 7 months ago

InMed Pharmaceuticals Proxy statement: Proxy Filing

Oct 24, 2025, 8:00 AM EDT - 7 months ago

InMed Pharmaceuticals Proxy statement: Proxy Filing

Oct 16, 2025, 8:30 AM EDT - 7 months ago

Inmed Pharmaceuticals Appoints Mr. John Bathery to Its Board of Directors

Oct 9, 2025, 8:30 AM EDT - 7 months ago

InMed Pharmaceuticals Appoints Mr. Neil Klompas to It's Board of Directors

ZYME

2025-09-23T12:45:20.000Z - 8 months ago

InMed Pharmaceuticals reports FY25 EPS ($8.36) vs ($20.14) last year

Sep 23, 2025, 8:30 AM EDT - 8 months ago

InMed Pharmaceuticals Reports Full Year Fiscal 2025 Financial Results and Provides Business Update

Sep 23, 2025, 7:00 AM EDT - 8 months ago

InMed Pharmaceuticals Earnings release: Q4 2025

Sep 23, 2025, 7:00 AM EDT - 8 months ago

InMed Pharmaceuticals Annual report: Q4 2025

Sep 18, 2025, 2:00 PM EDT - 8 months ago

InMed Pharmaceuticals Transcript: Life Sciences Virtual Investor Forum 2025

Sep 16, 2025, 1:39 PM EDT - 8 months ago

InMed to Present at the Life Sciences Virtual Investor Forum September 18th, 2025

Sep 5, 2025, 1:33 PM EDT - 9 months ago

InMed to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

Sep 4, 2025, 8:00 PM EDT - 9 months ago

InMed Pharmaceuticals Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Aug 1, 2025, 8:00 AM EDT - 10 months ago

InMed Pharmaceuticals Registration statement: Registration Filing

Jul 28, 2025, 7:00 AM EDT - 10 months ago

InMed to Present INM-901 Data at Alzheimer's Association International Conference (AAIC) 2025

2025-07-09T21:30:20.000Z - 11 months ago

InMed Pharmaceuticals files to sell 3.9M common shares for holders

Jul 9, 2025, 8:00 AM EDT - 11 months ago

InMed Pharmaceuticals Registration statement: Registration Filing

Jun 27, 2025, 7:00 AM EDT - 11 months ago

InMed Pharmaceuticals Announces Closing of $5 Million Private Placement Priced At-the-Market under Nasdaq Rules

2025-06-25T12:15:44.000Z - 11 months ago

InMed Pharmaceuticals announces $5M private placement

Jun 25, 2025, 8:00 AM EDT - 11 months ago

InMed Pharmaceuticals Announces $5 Million Private Placement Priced At-the-Market Under Nasdaq Rules

2025-06-24T11:45:17.000Z - 11 months ago

InMed Pharmaceuticals announces new preclinical data on INM-901

Jun 24, 2025, 7:00 AM EDT - 11 months ago

InMed's INM-901 Significantly Reduces Neuroinflammation in Alzheimer's Disease Ex Vivo Study

Jun 13, 2025, 4:30 PM EDT - 1 year ago

InMed Appoints CBIZ as New Auditor in Connection with CBIZ's Acquisition of Marcum's Attest Business, Provides Update on Special Meeting and Makes Modifications to Existing SEPA

May 29, 2025, 8:00 AM EDT - 1 year ago

InMed Pharmaceuticals Proxy statement: Proxy Filing

2025-05-16T15:45:48.000Z - 1 year ago

Biotech Alert: Searches spiking for these stocks today

ADCT ALZN EXEL HUMA LEGN ONCO OTLK

May 16, 2025, 8:00 AM EDT - 1 year ago

InMed Pharmaceuticals Proxy statement: Proxy Filing

May 12, 2025, 6:00 PM EDT - 1 year ago

InMed Reports Third Quarter Fiscal 2025 Financial Results and Provides Business Update

May 11, 2025, 6:00 PM EDT - 1 year ago

InMed Pharmaceuticals Earnings release: Q3 2025

May 11, 2025, 6:00 PM EDT - 1 year ago

InMed Pharmaceuticals Quarterly report: Q3 2025

Apr 29, 2025, 8:00 AM EDT - 1 year ago

InMed Pharmaceuticals Proxy statement: Proxy Filing

Feb 13, 2025, 4:00 PM EST - 1 year ago

InMed Pharmaceuticals Quarterly report: Q2 2025

2025-02-13T00:05:04.000Z - 1 year ago

InMed Pharmaceuticals reports Q2 EPS ($3.64) vs ($3.71) last year

Feb 12, 2025, 6:54 PM EST - 1 year ago

InMed Reports Second Quarter Fiscal 2025 Financial Results and Provides Business Update

2025-02-03T12:45:43.000Z - 1 year ago

InMed Pharmaceuticals announces INM-089 IVT formulation as drug candidate

Feb 3, 2025, 7:30 AM EST - 1 year ago

InMed Announces INM-089 Intravitreal Formulation in the Treatment of Dry Age-Related Macular Degeneration

2025-01-24T16:00:34.000Z - 1 year ago

Biotech Alert: Searches spiking for these stocks today

DRMA DWTX GNLX LSTA MGX NTRB REPL

2025-01-22T12:45:10.000Z - 1 year ago

InMed Pharmaceuticals granted an international PCT patent

Jan 22, 2025, 7:30 AM EST - 1 year ago

InMed Pharmaceuticals Announces Granting of Patent for Novel Compounds

Jan 21, 2025, 7:30 AM EST - 1 year ago

InMed's INM-901 Demonstrates Statistically Significant Reduction in Neuroinflammation in a Long-Term Preclinical Alzheimer's Disease Study

Dec 30, 2024, 7:00 AM EST - 1 year ago

InMed Pharmaceuticals Registration statement: Registration Filing

Dec 23, 2024, 7:00 AM EST - 1 year ago

InMed Pharmaceuticals Registration statement: Registration Filing

Dec 18, 2024, 8:00 PM EST - 1 year ago

InMed Announces Results of 2024 Annual General Meeting

Dec 17, 2024, 4:56 PM EST - 1 year ago

InMed Enters Into Standby Equity Purchase Agreement

Nov 19, 2024, 7:30 AM EST - 1 year ago

InMed Announces Publication of Study on Anti-Inflammation by Modulation of Endocannabinoid System

Nov 14, 2024, 4:45 PM EST - 1 year ago

InMed Reports First Quarter Fiscal 2025 Financial Results and Provides Business Update

Nov 14, 2024, 9:30 AM EST - 1 year ago

InMed Pharmaceuticals Quarterly report: Q1 2025

Nov 12, 2024, 2:00 PM EST - 1 year ago

InMed Pharmaceuticals Transcript: Status Update

Nov 12, 2024, 2:00 PM EST - 1 year ago

InMed Pharmaceuticals Slides: Status Update

Nov 8, 2024, 4:44 PM EST - 1 year ago

InMed Announces Share Consolidation to Satisfy Nasdaq Listing Rules

Nov 5, 2024, 8:30 AM EST - 1 year ago

InMed Pharmaceuticals Announces Decision by NASDAQ Hearings Panel to Grant Exception to Implement Share Consolidation to Satisfy NASDAQ Listing Rules

Oct 28, 2024, 8:00 AM EDT - 1 year ago

InMed Pharmaceuticals Proxy statement: Proxy Filing

Oct 28, 2024, 8:00 AM EDT - 1 year ago

InMed Pharmaceuticals Proxy statement: Proxy Filing

Oct 28, 2024, 7:30 AM EDT - 1 year ago

InMed Pharmaceuticals Files Additional Patent Application for INM-901 in the Treatment of Neurodegenerative Conditions Including Alzheimer's Disease

Oct 24, 2024, 8:00 AM EDT - 1 year ago

InMed to Participate in Fierce Biotech Webinar on Neuroinflammation in Alzheimer's Disease

Oct 22, 2024, 8:00 AM EDT - 1 year ago

InMed Appoints Dr. Barry Greenberg, Johns Hopkins University School of Medicine, to its Scientific Advisory Board

Sep 30, 2024, 8:00 AM EDT - 1 year ago

InMed Pharmaceuticals Reports Full Year Fiscal 2024 Financial Results and Provides Business Update

Sep 30, 2024, 6:00 AM EDT - 1 year ago

InMed Pharmaceuticals Earnings release: Q4 2024

Sep 30, 2024, 6:00 AM EDT - 1 year ago

InMed Pharmaceuticals Annual report: Q4 2024

Sep 20, 2024, 4:30 PM EDT - 1 year ago

InMed Receives NASDAQ Delisting Notice, and Confirms it has Filed an Appeal and Obtained a Panel Hearing Date

Aug 21, 2024, 7:30 AM EDT - 1 year ago

InMed Pharmaceuticals Strengthens Patent Portfolio with Issuance of Three U.S. Patents

Aug 20, 2024, 7:30 AM EDT - 1 year ago

InMed Pharmaceuticals Demonstrates INM-901 as an Oral Formulation Targeting Alzheimer's Disease

Jul 30, 2024, 8:00 AM EDT - 1 year ago

InMed Pharmaceuticals Announces Favorable Behavioral Outcomes with INM-901 in Long-Term Preclinical Alzheimer's Disease Study, Confirming Previous Short-Term Pilot Study Data

Jun 13, 2024, 1:45 PM EDT - 2 years ago

InMed Pharmaceuticals Transcript: Emerging Growth Conference 72

Jun 10, 2024, 5:18 PM EDT - 2 years ago

InMed to Present at the Emerging Growth Conference

May 14, 2024, 4:00 PM EDT - 2 years ago

InMed Pharmaceuticals Quarterly report: Q3 2024

May 14, 2024, 8:30 AM EDT - 2 years ago

InMed Pharmaceuticals Reports Third Quarter Fiscal 2024 Financial Results and Provides Business Update

Apr 18, 2024, 8:00 AM EDT - 2 years ago

InMed Appoints Dr. David G. Morgan, PhD, a Leading Alzheimer's Expert, to the Company's Scientific Advisory Board

Apr 16, 2024, 8:00 AM EDT - 2 years ago

InMed Provides Update on INM-089 in the Treatment of Dry Age-Related Macular Degeneration

Apr 4, 2024, 8:00 AM EDT - 2 years ago

InMed's INM-901 Demonstrates Favorable Pharmacological and Behavioral Effects in In Vivo Preclinical Alzheimer's Disease Studies

Mar 20, 2024, 8:30 AM EDT - 2 years ago

InMed Granted 180-Day Extension to Achieve Nasdaq Minimum Bid Compliance